The role of clusterin (CLU) in malignant transformation and drug resistance in breast carcinomas

Advances in Cancer Research

Volumn 105, Issue , 2009, Pages 21-43

  Redondo, Maximino ^a   Tellez, Teresa ^a   Roldan, María Jose ^a  

^a UNIVERSITY OF MÁLAGA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CLU PROTEIN, HUMAN; CLUSTERIN; DEXAMETHASONE; NUCLEOTIDE; OGX 011; OGX-011; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

APOPTOSIS; BREAST TUMOR; DRUG RESISTANCE; FEMALE; HUMAN; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; REVIEW;

APOPTOSIS; BREAST NEOPLASMS; CLUSTERIN; DEXAMETHASONE; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; PROGNOSIS; THIONUCLEOTIDES;

EID: 73949150866     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-230X(09)05002-7     Document Type: Review

References (100)

1. Aigelsreiter, A., Janig, E., Sostaric, J., Pichler, M., Unterthor, D., Halasz, J., Lackner, C., Zatloukal, K., and Denk, H. (2009). Clusterin expression in cholestasis, hepatocellular carcinoma and liver fibrosis. Histopathology 54, 561-570.
2. Albert, J. M., Gonzalez, A., Massion, P. P., Chen, H., Olson, S. J., Shyr, Y., Diaz, R., Lambright, E. S., Sandler, A., Carbone, D. P., Putnam, J.B, Jr., Johnson, D. H., et al. (2007). Cytoplasmic clusterin expression is associated with longer survival in patients with resected non small cell lung cancer. Cancer Epidemiol. Biomarkers Prev. 16, 1845-1851.
3. Amsterdam, A., and Sasson, R. (2002). The anti-inflammatory action of glucocorticoids is mediated by cell type specific regulation of apoptosis. Mol. Cell. Endocrinol. 189, 1-9.
4. Andersen, C. L., Schepeler, T., Thorsen, K., Birkenkamp-Demtrö der, K., Mansilla, F., Aaltonen, L. A., Laurberg, S., and Ørntoft, T. F. (2007). Clusterin expression in normal mucosa and colorectal cancer. Mol. Cell. Proteomics 6, 1039-1048.
5. Appel, D., Pilarsky, C., Graichen, R., and Koch-Brandt, C. (1996). Sorting of gp80 (GPIII, clusterin), a marker protein for constitutive apical secretion in Madin-Darby canine kidney (MDCK) cells, into the regulated pathway in the pheochromocytoma cell line PC12. Eur. J. Cell Biol. 70, 142-149.
6. Bettuzzi, S., Hiipakka, R. A., Gilna, P., and Liao, S. T. (1989). Identification of an androgenrepressed mRNA in rat ventral prostate as coding for sulphated glycoprotein 2 by cDNA cloning and sequence analysis. Biochem. J. 257, 293-296.
7. Bettuzzi, S., Scorcioni, F., Astancolle, S., Davalli, P., Scaltriti, M., and Corti, A. (2002). Clusterin (SGP-2) transient overexpression decreases proliferation rate of SV40-immortalized human prostate epithelial cells by slowing down cell cycle progression. Oncogene 21, 4328-4334.
8. Biroccio, A., D'Angelo, C., Cansen, B., Gleave, M. E., and Zupi, G. (2005). Antisense clusterin oligodeoxynucleotides increase the response of HER-2 gene amplified breast cancer cells to Trastuzumab. Cell. Physiol. 204, 463-469.
9. Blaschuk, O., Burdzy, K., and Fritz, I. B. (1983). Purification and characterization of a cellaggregating factor (clusterin), the major glycoprotein in ram rete testis fluid. J. Biol. Chem. 258, 7714-7720.
10. Busam, K. J., Kucukgol, D., Eastlake-Wade, S., Frosina, D., Delgado, R., and Jungbluth, A. A. (2006). Clusterin expression in primary and metastatic melanoma. J. Cutan. Pathol. 33, 619-623.
11. 2+ depletion induces nuclear clusterin, a novel effector of apoptosis in immortalized human prostate cells. Cell Death Differ. 12, 101-104.
12. Cappelletti, V., Gariboldi, M., De Cecco, L., Toffanin, S., Reid, J. F., Lusa, L., Bajetta, E., Celio, L., Greco, M., Fabbri, A., Pierotti, M. A., and Daidone, M. G. (2008). Patterns and changes in gene expression following neo-adjuvant anti-estrogen treatment in estrogen receptor-positive breast cancer. Endocr. Relat. Cancer 15, 439-449.
13. Cervellera, M., Raschella, G., Santilli, G., Tanno, B., Ventura, A., Mancini, C., Sevignani, C., Calabretta, B., and Sala, A. (2000). Direct transactivation of the anti-apoptotic gene apolipoprotein J (clusterin) by B-MYB. J. Biol. Chem. 275, 21055-21060.
14. Chayka, O., Corvetta, D., Dews, M., Caccamo, A. E., Piotrowska, I., Santilli, G., Gibson, S., Sebire, N. J., Himoudi, N., Hogarty, M. D., Anderson, J., Bettuzzi, S., et al. (2009). Clusterin, a haploinsufficient tumor suppressor gene in neuroblastomas. J.Natl. Cancer Inst. 101, 663-677.
15. Chen, H., Tritton, T. R., Kenny, N., Absher, M., and Chiu, J. F. (1996). Tamoxifen induces TGFbeta 1 activity and apoptosis of humanMCF-7 breast cancer cells in vitro. J. Cell. Biochem. 61, 9-17.
16. Chen, X., Halberg, R. B., Ehrhardt, W. M., Torrealba, J., and Dove, W. F. (2003). Clusterin as a biomarker in murine and human intestinal neoplasia. Proc. Natl. Acad. Sci. USA 100, 9530-9535.
17. Chen, T., Turner, J., McCarthy, S., Scaltriti, M., Bettuzzi, S., and Yeatman, T. J. (2004). Clusterin-mediated apoptosis is regulated by adenomatous polyposis coli and is p21 dependent but p53 independent. Cancer Res. 64, 7412-7419.
18. Chi, K. N., Eisenhauer, E., Fazli, L., Jones, E. C., Goldenberg, S. L., Powers, J., Tu, D., and Gleave, M. E. (2005). A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J. Natl. Cancer Inst. 97, 1287-1296.
19. Chi, K. N., Siu, L. L., Hirte, H., Hotte, S. J., Knox, J., Kollmansberger, C., Gleave, M., Guns, E., Powers, J., Walsh, W., Tu, D., and Eisenhauer, E. (2008). A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin. Cancer Res. 14, 833-839.
20. Chia, S., Dent, S., Ellard, S., Ellis, P. M., Vandenberg, T., Gelmon, K., Powers, J., Walsh, W., Seymour, L., and Eisenhauer, E. A. (2009). Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer. Clin. Cancer Res. 15, 708-713.
21. Chung, J., Kwak, C., Jin, R. J., Lee, C. H., Lee, K. H., and Lee, S. E. (2004). Enhanced chemosensitivity of bladder cancer cells to cisplatin by suppression of clusterin in vitro. Cancer Lett. 203, 155-161.
22. Criswell, T., Klokov, D., Beman, M., Lavik, J. P., and Boothman, D. A. (2003). Repression of IR-inducible clusterin expression by the p53 tumor suppressor protein. Cancer Biol. Ther. 2, 372-380.
23. Doustjalali, S. R., Yusof, R., Yip, C. H., Looi, L. M., Pillay, B., and Hashim, O. H. (2004). Aberrant expression of acute-phase reactant proteins in sera and breast lesions of patients with malignant and benign breast tumors. Electrophoresis 25, 2392-2401.
24. Early Breast Cancer Trialists' Collaborative Group(2000). Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: An overview of the randomised trials. Lancet 355, 1757-1770.
25. Fritz, I. B., Burdzy, C., Setchell, B., and Blaschuck, O. (1983). Ram rete testes fluid contains a protein (clusterin) which influence cell-cell interactions in vitro. Biol. Reprod. 28, 1173-1188.
26. Gleave, M., and Jansen, B. (2003). Clusterin and IGFBPs as antisense targets in prostate cancer. Ann. N. Y. Acad. Sci. 1002, 95-104.
27. Gleave, M., and Miyake, H. (2005). Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer. World J. Urol. 23, 38-46.
28. Gleave, M. E., Miyake, H., Zellweger, T., Chi, K., July, L., Nelson, C., and Rennie, P. (2001). Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosteronerepressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer. Urology 58, 39-49.
29. Hasan, Q., Tan, S. T., Xu, B., and Davis, P. F. (2003). Effects of five commonly used glucocorticoids on haemangioma in vitro. Clin. Exp. Pharmacol. Physiol. 30, 140-144.
30. Humphreys, D. T., Carver, J. A., Easterbroock Smith, S. B., and Wilson, M. R. (1999). Clusterin has chaperone like activity similar to that of small heat shock protein. J. Biol. Chem. 274, 6875-6881.
31. Imai, M., Hwang, H. Y., Norris, J. S., and Tomlinson, S. (2004). The effect of dexamethasone on human mucin 1 expression and antibody-dependent complement sensitivity in a prostate cancer cell line in vitro and in vivo. Immunology 111, 291-297.
32. Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, E. J., and Thun, M. J. (2005). Cancer statistics, 2005. CA Cancer J. Clin. 55, 10-30.
33. Jenne, D. E., and Tschopp, J. (1992). Clusterin: The intriguing guises of a widely expressed glycoprotein. Trends Biochem. Sci. 17, 154-159.
34. Jordan Stark, T. C., Witte, D. P., Aronow, B., and Harmony, J. A. K. (1992). Apolipoprotein J: A membrane policeman? Curr. Opin. Lipidol. 3, 75-85.
35. July, L. V., Akbari, M., Zellweger, T., Jones, E. C., Goldenberg, S. L., and Gleave, M. E. (2002). Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 50, 179-188.
36. July, L. V., Beraldi, E., So, A., Fazli, L., Evans, K., English, J. C., and Gleave, M. E. (2004). Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. Mol. Cancer Ther. 3, 223-232.
37. Kang, Y. K., Hong, S.W., Lee, H., and Kim, W. H. (2004). Overexpression of clusterin in human hepatocellular carcinoma. Hum. Pathol. 35, 1340-1346.
38. Kevans, D., Foley, J., Tenniswood, M., Sheahan, K., Hyland, J., O'Donoghue, D., Mulcahy, H., and O'Sullivan, J. (2009). High clusterin expression correlates with a poor outcome in stage II colorectal cancers. Cancer Epidemiol. Biomarkers Prev. 18, 393-399.
39. Kissinger, C., Skinner, M. K., and Griswold, M. D. (1982). Analysis of Sertoli cell-secreted proteins by two-dimensional gel electrophoresis. Biol. Reprod. 27, 233-240.
40. Krüger, S., Mahnken, A., Kausch, I., and Feller, A. C. (2006). Value of clusterin immunoreactivity as a predictive factor in muscle-invasive urothelial bladder carcinoma. Urology 67, 105-109.
41. Krüger, S., Ola, V., Fischer, D., Feller, A. C., and Friedrich, M. (2007). Prognostic significance of clusterin immunoreactivity in breast cancer. Neoplasma 54, 46-50.
42. Kurahashi, T., Muramaki, M., Yamanaka, K., Hara, I., and Miyake, H. (2005). Expression of the secreted form of clusterin protein in renal cell carcinoma as a predictor of disease extension. BJU Int. 96, 895-899.
43. Kyprianou, N., English, H. F., Davidson, N. E., and Isaacs, J. T. (1991). Programmed cell death during regression of the MCF 7 human breast cancer following estrogen ablation. Cancer Res. 51, 162-166.
44. Lau, S. H., Sham, J. S., Xie, D., Tzang, C. H., Tang, D., Ma, N., Hu, L., Wang, Y., Wen, J. M., Xiao, G., Zhang, W. M., Lau, G. K., et al. (2006). Clusterin plays an important role in hepatocellular carcinoma metastasis. Oncogene 25, 1242-1250.
45. Leskov, K. S., Klokov, D. Y., Li, J., Kinsella, T. J., and Boothman, D. A. (2003). Synthesis and functional analyses of nuclear clusterin, a cell death protein. J. Biol. Chem. 278, 11590-11600.
46. Lund, P., Weisshaupt, K., Mikeska, T., Jammas, D., Chen, X., Kuban, R. J., Ungethüm, U., Krapfenbauer, U., Herzel, H. P., Schäfer, R., Walter, J., and Sers, C. (2006). Oncogenic HRAS suppresses clusterin expression through promoter hypermethylation. Oncogene 25, 4890-4903.
47. Mallory, J. C., Crudden, G., Oliva, A., Saunders, C., Stromberg, A., and Craven, R. J. (2005). A novel group of genes regulates susceptibility to antineoplastic drugs in highly tumorigenic breast cancer cells. Mol. Pharmacol. 68, 1747-1756.
48. Miyake, H., Chi, K. N., and Gleave, M. E. (2000a). Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin. Cancer Res. 6, 1655-1663.
49. Miyake, H., Nelson, C., Rennie, P. S., and Gleave, M. E. (2000b). Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Res. 60, 2547-2554.
50. Miyake, H., Hara, I., Kamidono, S., and Gleave, M. E. (2001a). Synergistic chemosensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Clin. Cancer Res. 7, 4245-4252.
51. Miyake, H., Hara, S., Zellweger, T., Kamidono, S., Gleave, M. E., and Hara, I. (2001b). Acquisition of resistance to Fas-mediated apoptosis by overexpression of clusterin in human renal-cell carcinoma cells. Mol. Urol. 5, 105-111.
52. Miyake, H., Hara, S., Arakawa, S., Kamidono, S., and Hara, I. (2002). Over expression of clusterin is an independent prognostic factor for nonpapillary renal cell carcinoma. J. Urol. 167, 703-706.
53. Miyake, H., Hara, I., Gleave, M. E., and Eto, H. (2004). Protection of androgen-dependent human prostate cancer cells from oxidative stress-induced DNAdamage by overexpression of clusterin and its modulation by androgen. Prostate 61, 318-323.
54. Miyake, H., Yamanaka, K., Muramaki, M., Hara, I., and Gleave, M. E. (2005a). Therapeutic efficacy of adenoviral-mediated p53 gene transfer is synergistically enhanced by combined use of antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Neoplasia 7, 171-179.
55. Miyake, H., Yamanaka, K., Muramaki, M., Kurahashi, T., Gleave, M., and Hara, I. (2005b). Enhanced expression of the secreted form of clusterin following neoadjuvant hormonal therapy as a prognostic predictor in patients undergoing radical prostatectomy for prostate cancer. Oncol. Rep. 14, 1371-1375.
56. Moretti, R. M., Marelli, M. M., Mai, S., Cariboni, A., Scaltriti, M., Bettuzzi, S., and Limonta, P. (2007). Clusterin isoforms differentially affect growth and motility of prostate cells: Possible implications in prostate tumorigenesis. Cancer Res. 67, 10325-10333.
57. Muramaki, M., So, A., Hayashi, N., Sowery, R., Miyake, H., Fujisawa, M., and Gleave, M. E. (2009). Chemosensitization of gemcitabine-resistant human bladder cancer cell line both in vitro and in vivo using antisense oligonucleotide targeting the anti-apoptotic gene, clusterin. BJU Int. 103, 384-390.
58. Parczyk, K., Pilarsky, C., Rachel, U., and Koch-Brandt, C. (1994). Gp80 (Clusterin; TRPM2) mRNA level is enhanced in human renal clear cell carcinomas. J. Cancer Res. Clin. Oncol. 120, 186-188.
59. Park, D. C., Yeo, S. G., Wilson, M. R., Yerbury, J. J., Kwong, J., Welch, W. R., Choi, Y. K., Birrer, M. J., Mok, S. C., and Wong, K. K. (2008). Clusterin interacts with Paclitaxel and confers Paclitaxel resistance in ovarian cancer. Neoplasia 10, 964-972.
60. Pasinetti, G. M., Johnson, S. A., Oda, T., Rozovsky, I., and Finch, C. E. (1994). Clusterin (SGP-2): A multifunctional glycoprotein with regional expression in astrocytes and neurons of the adult rat brain. J. Comp. Neurol 339, 387-400.
61. Pins, M. R., Fiadjoe, J. E., Korley, F., Wong, M., Rademaker, A. W., Jovanovic, B., Yoo, T. K., Kozlowski, J. M., Raji, A., Yang, X. J., and Lee, C. (2004). Clusterin as a possible predictor for biochemical recurrence of prostate cancer following radical prostatectomy with intermediate Gleason scores: A preliminary report. Prostate Cancer Prostatic Dis. 7, 243-248.
62. Pucci, S., Bonanno, E., Pichiorri, F., Angeloni, C., and Spagnoli, L. G. (2004). Modulation of different clusterin isoforms in human colon tumorigenesis. Oncogene 23, 2298-2304.
63. Rauhala, H. E., Porkka, K. P., Saramäki, O. R., Tammela, T. L., and Visakorpi, T. (2008). Clusterin is epigenetically regulated in prostate cancer. Int. J. Cancer 123, 1601-1609.
64. Ravdin, P. M., Cronin, K. A., Howlader, N., Berg, C. D., Chlebowski, R. T., Feuer, E. J., Edwards, B. K., and Berry, D. A. (2007). The decrease in breast-cancer incidence in 2003 in the United States. N. Engl. J. Med. 356, 1670-1674.
65. Reddy, K. B., Jin, G., Karode, M. C., Harmony, J. A., and Howe, P. H. (1996). Transforming growth factor beta (TGF beta)-induced nuclear localization of apolipoprotein J/clusterin in epithelial cells. Biochemistry 35, 6157-6163.
66. Redondo, M., Villar, E., Torres-Muñoz, J., Tellez, T., Morell, M., and Petito, C. K. (2000). Overexpression of clusterin in human breast carcinoma. Am. J. Pathol. 157, 393-399.
67. Redondo, M., García, J., Villar, E., Rodrigo, I., Perea-Milla, E., Serrano, A., and Morell, M. (2003). Major histocompatibility complex status in breast carcinogenesis and relationship to apoptosis. Hum. Pathol. 34, 1283-1289.
68. Redondo, M., Esteban, F., Gonzalez-Moles, M. A., Delgado-Rodriguez, M., Nevado, M., Torres-Muñoz, J. E., Tellez, T., Villar, E., Morell, M., and Petito, C. K. (2006). Expression of the antiapoptotic proteins clusterin and bcl-2 in laryngeal squamous cell carcinomas. Tumour Biol. 27, 195-200.
69. Redondo, M., Téllez, T., Roldan, M. J., Serrano, A., García-Aranda, M., Gleave, M. E., Hortas, M. L., and Morell, M. (2007). Anticlusterin treatment of breast cancer cells increases the sensitivities of chemotherapy and tamoxifen and counteracts the inhibitory action of dexamethasone on chemotherapy-induced cytotoxicity. Breast Cancer Res. 9, R86.
70. Redondo, M., Funez, R., and Esteban, F. (2009). Apoptosis in the development and treatment of laryngel cancer: Role of p53, bcl-2 and clusterin. In "Apoptosis in Carcinogenesis and Chemotherapy," (G. Chen and P. B. S. Lai, Eds.), Vol. 10, pp. 237-249. Springer, Netherlands.
71. Santilli, G., Aronow, B. J., and Sala, A. (2003). Essential requirement of apolipoprotein J (clusterin) signaling for IkappaB expression and regulation of NF-kappaB activity. J. Biol. Chem. 278, 38214-38219.
72. Scaltriti, M., Bettuzzi, S., Sharrard, R. M., Caporali, A., Caccamo, A. E., and Maitland, N. J. (2004). Clusterin overexpression in both malignant and nonmalignant prostate epithelial cells induces cell cycle arrest and apoptosis. Br. J. Cancer 91, 1842-1850.
73. Sensibar, J. A., Griswold, M. D., Sylvester, S. R., Buttyan, R., Bardin, C. W., Cheng, C. Y., Dudek, S., and Lee, C. (1991). Prostatic ductal system in rats: regional variation in localization of an androgen-repressed gene product, sulfated glycoprotein-2. Endocrinology 128, 2091-2102.
74. Sensibar, J. A., Sutkowski, D. M., Raffo, A., Buttyan, R., Griswold, M. D., Sylvester, S. R., Kozlowskim, J. M., and Lee, C. (1995). Prevention of cell death induced by tumor necrosis factor alpha in LNCaP cells by overexpression of sulfated glycoprotein-2 (clusterin). Cancer Res. 55, 2431-2437.
75. So, A., Sinnemann, S., Huntsmann, D., Fazli, L., and Gleave, M. (2005). Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo. Mol. Cancer Ther. 4, 1837-1849.
76. Steinberg, J., Oyasu, R., Lang, S., Sintich, S., Rademaker, A., Lee, C., Kozlowski, J. M., and Sensibar, J. A. (1997). Intracellular levels of SGP-2 (clusterin) correlate with tumor grade in prostate cancer. Clin. Cancer Res. 3, 1707-1711.
77. Sun, B., Zhang, S., Zhang, D., Liu, Y., Li, Y., Rong, Z., Zhu, Y., and Jia, X. (2007). Clusterin is associated with spontaneous breast cancer in TA2 mice. FEBS Lett. 581, 3277-3282.
78. Thomas-Tikhonenko, A., Viard-Leveugle, I., Dews, M., Wehrli, P., Sevignani, C., Yu, D., Ricci, S., El-Deiry, W., Aronow, B., Kaya, G., Saurat, J. H., and French, L. E. (2004). Myctransformed epithelial cells down-regulate clusterin, which inhibits their growth in vitro and carcinogenesis in vivo. Cancer Res. 64, 3126-3136.
79. Toffanin, S., Daidone, M. G., Miodini, P., De Cecco, L., Gandellini, P., and Cappelletti, V. (2008). Clusterin: A potential target for improving response to antiestrogens. Int. J. Oncol. 33, 791-798.
80. Trougakos, I. P., and Gonos, E. S. (2002). Clusterin/Apolipoprotein J in human aging and cancer. Int. J. Biochem. Cell Biol. 34, 1430-1448.
81. Trougakos, I. P., So, A., Jansen, B., Gleave, M. E., and Gonos, E. S. (2004). Silencing expression of the clusterin/apolipoprotein J gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress. Cancer Res. 64, 1834-1842.
82. Trougakos, I. P., Lourda, M., Agiostratidou, G., Kletsas, D., and Gonos, E. S. (2005). Differential effects of clusterin/apolipoprotein J on cellular growth and survival. Free Radic. Biol. Med. 38, 436-449.
83. Trougakos, I. P., Djeu, J. Y., Gonos, E. S., and Boothman, D. A. (2009a). Advances and challenges in basic and translational research on clusterin. Cancer Res. 69, 403-406.
84. Trougakos, I. P., Lourda, M., Antonelou, M. H., Kletsas, D., Gorgoulis, V. G., Papassideri, I. S., Zou, Y., Margaritis, L. H., Boothman, D. A., and Gonos, E. S. (2009b). Intracellular clusterin inhibits mitochondrial apoptosis by suppressing p53-activating stress signals and stabilizing the cytosolic Ku70-Bax protein complex. Clin. Cancer Res. 15, 48-59.
85. Warri, A. M., Huovinen, R. L., Laine, A. M., Martikainen, P. M., and Harkonen, P. L. (1993). Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro. J. Natl. Cancer Inst. 85, 1412-1418.
86. Watari, H., Ohta, Y., Hassan, M. K., Xiong, Y., Tanaka, S., and Sakuragi, N. (2008). Clusterin expression predicts survival of invasive cervical cancer patients treated with radical hysterectomy and systematic lymphadenectomy. Gynecol. Oncol. 108, 527-532.
87. Wu, W., Chaudhuri, S., Brickley, D. R., Pang, D., Karrison, T., and Conzen, S. D. (2004). Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res. 64, 1757-1764.
88. Xie, M. J., Motoo, Y., Su, S. B., Mouri, H., Ohtsubo, K., Matsubara, F., and Sawabu, N. (2002). Expression of clusterin in human pancreatic cancer. Pancreas 25, 234-238.
89. Xie, D., Lau, S. H., Sham, J. S., Wu, Q. L., Fang, Y., Liang, L. Z., Che, L. H., Zeng, Y. X., and Guan, X. Y. (2005a). Up-regulated expression of cytoplasmic clusterin in human ovarian carcinoma. Cancer 103, 277-283.
90. Xie, D., Sham, J. S., Zeng, W. F., Che, L. H., Zhang, M., Wu, H. X., Lin, H. L., Wen, J. M., Lau, S. H., Hu, L., and Guan, X. Y. (2005b). Oncogenic role of clusterin overexpression in multistage colorectal tumorigenesis and progression. World J. Gastroenterol. 11, 3285-3289.
91. Yamanaka, K., Gleave, M. E., Hara, I., Muramaki, M., and Miyake, H. (2005). Synergistic antitumor effect of combined use of adenoviral-mediated p53 gene transfer and antisense oligodeoxynucleotide targeting clusterin gene in an androgen-independent human prostate cancer model. Mol. Cancer Ther. 4, 187-195.
92. Yang, C. R., Yeh, S., Leskov, K., Odegaard, E., Hsu, H. L., Chang, C., Kinsella, T. J., Chen, D. J., and Boothman, D. A. (1999). Isolation of Ku70-binding proteins (KUBs). Nucleic Acids Res. 27, 2165-2174.
93. Yang, C. R., Leskov, K., Hosley-Eberlein, K., Criswell, T., Pink, J. J., Kinsella, T. J., and Boothman, D. A. (2000). Nuclear clusterin/XIP8, an X-ray-induced Ku70-binding protein that signals cell death. Proc. Natl. Acad. Sci. USA 97, 5907-5912.
94. Zellweger, T., Miyake, H., July, L. V., Akbari, M., Kiyama, S., and Gleave, M. E. (2001a). Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. Neoplasia 3, 360-367.
95. Zellweger, T., Miyake, H., Cooper, S., Chi, K., Conklin, B. S., Monia, B. P., and Gleave, M. E. (2001b). Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy)ethyl chemistry. J. Pharmacol. Exp. Ther. 298, 934-940.
96. Zellweger, T., Chi, K., Miyake, H., Adomat, H., Kiyama, S., Skov, K., and Gleave, M. E. (2002). Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin. Cancer Res. 8, 3276-3284.
97. Zellweger, T., Kiyama, S., Chi, K., Miyake, H., Adomat, H., Skov, K., and Gleave, M. E. (2003). Overexpression of the cytoprotective protein clusterin decreases radiosensitivity in the human LNCaP prostate tumour model. BJU Int. 92, 463-469.
98. Zhang, L. Y., Ying, W. T., Mao, Y. S., He, H. Z., Liu, Y., Wang, H. X., Liu, F., Wang, K., Zhang, D. C., Wang, Y., Wu, M., Qian, X. H., et al. (2003). Loss of clusterin both in serum and tissue correlates with the tumorigenesis of esophageal squamous cell carcinoma via proteomics approaches. World J. Gastroenterol. 9, 650-654.
99. Zhang, H., Kim, J. K., Edwards, C. A., Xu, Z., Taichman, R., andWang, C. Y. (2005). Clusterin inhibits apoptosis by interacting with activated Bax. Nat. Cell Biol. 7, 909-915.
100. Zhang, S., Zhang, D., Zhu, Y., Guo, H., Zhao, X., and Sun, B. (2006). Clusterin expression and univariate analysis of overall survival in human breast cancer. Technol. Cancer Res. Treat. 5, 573-578.